4730-54-5,4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated
1,4,7-Triazacyclononane (41 mg, 0.32 mmol, 1 equiv.) and6-(bromomethyl)-2-methyl-3-nitropyridine. (258 mg, 1.12 mmol, 3.5 equiv.) were dissolved in 8 mL of dry acetonitrile followed by addition of triethylamine (180 .iL, 1.29 mmol, 4 equiv.). The reaction mixture was stirred at 50 C for 24 hours under argon. Upon completion of the reaction, solvent was removed in vacuo producing a brown oily residue. The crudeproduct was purified by reversed-phase HPLC using a gradient of solvent B from 30% to70% in solvent A over 40 minutes. ESI-MS analyses of fractions with retention time tR = 21minute confirmed product iv. These fractions were combined and solvent was removed bylyophilization producing iv in the form of TFA salt. Yield: 80 mg, 63 .imol, 20%. ?H NMR,500 MHz (CD3OD, ppm): oe = 8.35 d (3H, Ar, J = 9 Hz), 7.55 d (3H, Ar, J = 9 Hz), 4.32 s(6H, 3CH2), 3.23 m (12H, 6CH2), 2.78 s (9H, 3CH3). ?3C NMR, 75 MHz (CD3OD, ppm): oe =160.60, 154.51, 146.59, 134.91, 123.40, 60.07, 50.74, 23.92. High-resolution ESI-MS (mlz):[M+H], calculated: 580.2627, found: 580.2691.
As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.
Reference£º
Patent; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK UNIVERSITY AT BUFFALO; HEALTH RESEARCH, INC.; MORROW, Janet, R.; TSITOVICH, Pavel, B.; DORAZIO, Sarina, J.; OLATUNDE, Abiola, O.; SNYDER, Eric, M.; SPERNYAK, Joseph, A.; BURNS, Patrick; BOND, Christopher, J.; WO2015/38943; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI